UK study will measure PFAS in blood and urine for the first time across a national sample
The UK has begun its first national effort to measure PFAS, the so-called “forever chemicals” that persist in the environment and can accumulate in human tissues. The program will use blood and urine samples from the existing Health Survey for England to establish baseline levels of PFAS alongside lead, arsenic, bisphenols, phthalates and flame retardants. In practical terms, the study is designed to answer a basic but long-unresolved question: how much of these compounds are already circulating in the UK population, and how does that exposure compare with what is known about health risk?
PFAS have been used since the 1940s and 1950s because they repel water, oil and heat. That durability made them useful in non-stick cookware, clothing, firefighting foams and many industrial products, but the same chemical stability also means they resist environmental breakdown. Once these compounds leak into soil and waterways, they can spread widely and remain present for years. The public health concern is not simply contamination of a site, but the possibility of chronic, low-level exposure in communities far from the original source.
Baseline measurement matters because exposure has usually been inferred rather than systematically mapped. Without population-wide biomonitoring, clinicians and regulators are left with scattered case reports, localized testing and incomplete environmental data.
Why the study is being launched now
UK health officials say current evidence suggests the likely health impact of PFAS is limited, but the strongest associations found in large population groups have linked exposure with raised cholesterol and lower birth weights. Two compounds, PFOA and PFOS, are already banned in the UK. Prolonged exposure to them can increase cancer risk, according to the World Health Organization, and broader research has associated them with reduced antibody responses after childhood vaccination, endocrine effects involving the thyroid and alterations in birth weight.
The scale of the PFAS family is part of the problem. More than 15,000 types are under discussion or review, and most have not been studied with the same depth as the better-known legacy compounds. Newer variants may differ in toxicity, persistence and biological behavior, yet public health surveillance still has to work with a patchy evidence base. A national biomonitoring study gives researchers a chance to capture the background exposure that already exists before trying to interpret future disease patterns.
Dr Edward Wynne-Evans, who leads radiation, chemicals, climate and environmental hazards at the UK Health Security Agency, pointed to a major gap in understanding: what different levels of exposure mean for an individual’s long-term health. That uncertainty is precisely why population data are needed. Individual blood tests can identify whether PFAS are present, but they do not automatically translate into a clinical action plan.
Blood tests can identify exposure, but not a treatment target
Routine PFAS testing is not recommended for the general public in the UK because there is no established clinical intervention for elevated levels. Wynne-Evans drew a direct line between diagnostic utility and medical action: if a test cannot reasonably lead to a recommended next step, routine use is difficult to justify. For patients, that reality can feel unsatisfying, especially in communities near known contamination sites where anxiety is high and the desire for personal results is understandable.
One punchline of the current evidence base is blunt. A blood result alone does not change the body burden that produced it.
That does not make the testing meaningless. It shifts the value from individual diagnosis toward population surveillance, environmental accountability and future risk stratification. In a setting where exposure is ongoing, the most effective intervention remains source control: stopping the release, removing the contamination and preventing further uptake into local water, soil and food chains. Biological monitoring cannot substitute for that.
Community concern is rising near contaminated sites
Interest in PFAS has intensified among people living near sites where contamination has already been documented. In September, blood tests in dozens of residents near a major chemical factory found really high levels of one of the cancer-causing forever chemicals, PFOA. Those findings sharpen the public debate, because they show how chemical exposure can become a direct issue for families living near industrial sites, rather than an abstract environmental hazard.
Prof Tony Fletcher of the London School of Hygiene & Tropical Medicine said low levels of PFAS are likely present in everyone’s blood. His point reflects what biomonitoring studies generally show: these compounds are widespread enough that background detection is expected, even in people without obvious industrial exposure. The critical difference lies in dose. Higher levels, and especially exposure in larger populations, have been associated with adverse health effects, even if the absolute risk for any one person remains relatively small.
What the first results may clarify next year
The first results are expected next year, and they should provide an important reference point for the UK. By placing PFAS measurements alongside other contaminants such as lead and arsenic, the study may also help public health researchers compare different exposure burdens within the same population framework. That could matter for future policy, because environmental contaminants rarely arrive alone; communities exposed to one class of chemicals are often exposed to several others at once.
The study will not settle every question. It will not, by itself, prove which exposure level causes which disease outcome, nor will it deliver a clinical fix for people already found to have elevated PFAS in their blood. What it can do is establish a national baseline, improve risk communication and give regulators better evidence for deciding where the biggest hazards lie.
For patients and clinicians, the practical message is direct. PFAS testing is becoming more scientifically grounded, but the immediate priority remains preventing ongoing exposure rather than chasing a number on a lab report. As the UKHSA begins to map the body burden of these persistent chemicals, the real test will be whether that evidence leads to cleaner water, safer consumer products and stronger action at contaminated sites.